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Inherited autoinflammatory diseases are secondary to mutations of proteins playing a piv-
otal role in the regulation of the innate immunity leading to seemingly unprovoked episodes
of inflammation.The understanding of the molecular pathways involved in these disorders
has shed new lights on the pattern of activation and maintenance of the inflammatory
response and disclosed new molecular therapeutic targets. Cryopyrin-associated periodic
syndrome (CAPS) represents the prototype of an autoinflammatory disease. The study of
the pathophysiological consequence of mutations in the cryopyrin gene (NLRP3) allowed
the identification of intracellular pathways responsible for the activation and secretion
of the potent inflammatory cytokine interleukin-1β (IL-1β). It became clear that several
multi-factorial inflammatory conditions display a number of pathogenic and clinical similar-
ities with inherited autoinflammatory diseases. The dramatic effect of interleukin-1 (IL-1)
blockade in CAPS opened new perspectives for the treatment of other inherited and multi-
factorial autoinflammatory disorders. Several IL-1 blockers are now available on the market.
In this review we outline the more recent novelties in the treatment with different IL-1
blockers in inherited and multi-factorial autoinflammatory diseases.
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INTRODUCTION
The Autoinflammatory Syndromes are a number of different con-
ditions characterized by episodes of inflammation secondary to
an activation of the innate arm of the immune response, in the
absence of high-titer auto-antibodies or antigen-specific T cells
(1). The term “Autoinflammatory diseases” was originally referred
to a limited number of rare inherited diseases identified as periodic
fevers. Under this term were gathered some monogenic diseases
featured by periodic or recurrent episodes of systemic inflam-
mation causing fever often associated with rash, serositis, lym-
phadenopathy, arthritis, and other clinical manifestations. These
disorders were secondary to mutations of genes coding for pro-
teins that play a pivotal role in the regulation of the inflammatory
response. In the following years the discovery of new genes and
novel inherited conditions allowed to clarify that the possible clini-
cal presentation of these new diseases was much wider and that the
term of periodic fevers was associated to a reductivist view of the
clinical phenotype possibly associated to this group of disorders
(Table 1).
In the meanwhile, the pathogenetic insights derived from stud-
ies on these rare disorders allowed a better understanding of
mechanisms responsible for the induction and maintenance of
inflammation and have set the basis for the identification of mol-
ecular targets for treatment. Due to the enormous interest raised
by the identification of NLRP3 Inflammasome (2) and by the
dramatic response to interleukin-1 (IL-1) blockers observed in
patients presenting a gain of function mutation of NLRP3 gene
(cryopyrin-associated periodic syndromes, CAPSs) (3–5), IL-1, is
now considered the pivotal pro-inflammatory cytokine in these
disorders. The availability of specific IL-1 targeting agents has
revealed a pathological role of IL-1-mediated inflammation in a
growing list of multi-factorial diseases in which a deregulation of
the same intracellular pathway probably occurs. Aim of the present
review is to provide a state of the art of the treatment of inherited
and multi-factorial autoinflammatory diseases with IL-1 blockers.
ANTI-IL-1 AGENTS
There are two related but distinct IL-1 genes, IL1A and IL1B,
encoding IL-1α and IL-1β, respectively. The IL-1α precursor is
constitutively present, in an active form, in most of the cells of
healthy individuals. Under disease conditions, IL-1α moves to
the cell’s surface membrane where it can activate adjacent cells
bearing the IL-1 receptor (6, 7). Conversely IL-1β is a prod-
uct of a limited type of cells (e.g., blood monocytes, tissue
macrophages, and dendritic cells). In physiological conditions
IL-1β is in an inactive form and requires a series of intracel-
lular events to be activated. In normal conditions both IL-1α
and IL-1β bind to type 1 IL-1 receptor (IL-1R1) and to the
adaptor protein IL-1RAcP in order to trigger signal transduction
(Figure 1).
Targeting IL-1 started in 1993 with the introduction of a recom-
binant non-glycosylated form of the naturally occurring IL-1
receptor antagonist (IL-1Ra, Anakinra), which blocks the activ-
ity of both IL-1α and IL-1β. IL-1Ra competes with free IL-1α
and IL-1β for the IL-1R1 binding but not with the adaptor pro-
tein, thus preventing signal transduction. Anakinra has a short
terminal half-life ranging from 4 to 6 h and it is administered
subcutaneously daily. Other IL-1 blockers have been successively
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Table 1 | Clinical classification of inherited and multi-factorial autoinflammatory diseases (AID).





















PAPA (CD2BP1, AD) CRMO
DIRA (IL1RN, AR) SAPHO
DITRA (IL36RN, AR) Gout and pseudogout
Majeed syndrome (LPIN2, AR) HLA-B27 spondyloarthropathy
CAMPS (CARD14, AD) Reactive arthritis
Blau’s syndrome (CARD15, AD) Sweet syndrome
Generalized pustular psoriasis
Hallopeau acrodermatitis
Panniculitis/lipodystrophy Nakajo–Nishimura (PSMB8, AR) Neutrophilic panniculitis
JMP (PSMB8, AR) Erythema nodosum and panniculitis
CANDLE syndrome (PSMB8, AR)
Inflammatory bowel disease Early-onset inflammatory bowel disease (IL10, IL10RA, IL10RB) Crohn’s disease
Hemophagocytic
lymphohistiocytosis
FHL1 (Unknown) SoJIA-associated MAS
FHL2 (PFR1/perforin 1, AR) Infection-associated MAS
FHL3 (UNC13D/Munc 13-4, AR)
FHL4 (STX11/syntaxin 11, AR)
FHL5 (STXB2/syntaxin binding protein, AR)
FMF, familial Mediterranean fever; FCAS, familiar cold autoinflammatory syndrome; MWS, Muckle–Wells syndrome; TRAPS, TNF-receptos associated periodic syn-
drome; MVK, mevalonate kinase deficiency; CINCA, chronic infantile neurological cutaneous and articular; PAPA, pyogenic sterile arthritis, pyoderma gangrenosum,
and acne; JMP, joint contractures, muscle atrophy, microcytic anemia, and panniculitis-induced childhood-onset lipodystrophy; CANDLE, chronic atypical neutrophilic
dermatosis with lipodystrophy and elevated temperature; DIRA, deficiency of the IL-1 receptor antagonist; DITRA, deficiency of IL-36 receptor antagonist; CAMPS,
CARD14-mediated pustular psoriasis; FHL, familial hemophagocytic lymphohistiocytosis; MAS, macrophage activation syndrome; AR, autosomal recessive; AD,
autosomal dominant.
developed. Rilonacept is a protein consisting of the extracellular
domains of humanized IL-1 type 1 receptor and the IL-1 receptor
accessory protein fused with the Fc portion of IgG1. Rilonacept
which has a terminal half-life of 6.3–8.6 days and is adminis-
tered once weekly, binds IL-1β and IL-1α with high affinity and
powerfully inhibits IL-1 activity.
Canakinumab is a fully human anti-interleukin-1β (IL-1β)
monoclonal antibody that selectively blocks IL-1β with high affin-
ity and does not cross-react with IL-1α or IL-1Ra. Binding to
IL-1β prevents the cytokine from the interaction with its receptor
and, thus, blocks the inflammatory signaling cascade. Compared
to other IL-1 blockers, Canakinumab provides a longer plasma
half-life (21–28 days).
Recently a novel compound called Gevokizumab has been
developed. Gevokizumab is a IgG2 humanized mAb that mod-
ulates IL-1β bioactivity by reducing the affinity for its IL-1RI:IL-
1RAcP signaling complex. It binds to a single IL-1β epitope where
residues critical for binding have been identified. It has a long
plasma half-life, which would allow once-monthly administration.
Some clinical trials are ongoing in osteoarthritis, non-infectious
uveitis, Pyoderma Gangrenosum, and Diabetes mellitus1.
Other therapeutic approaches, including IL-1α neutralization,
a therapeutic vaccine targeting IL-1β, and a chimeric IL-1Ra,
are in early clinical trials. Moreover, orally active small-molecule
inhibitors of IL-1 production, such as Caspase 1 inhibitors, have
been developed and are being tested (8, 9).
MONOGENIC AUTOINFLAMMATORY DISEASES
CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME
Familiar Cold Autoinflammatory Syndrome (FCAS), Muckle–
Wells Syndrome (MWS), and Chronic Infantile Neurological
Cutaneous and Articular Syndrome (CINCA) or Neonatal Onset
Multi-systemic Inflammatory Disease (NOMID) are three dis-
eases originally described as distinct entities that turned out to
belong to the wide clinical phenotype of disorders due to muta-
tions of NLRP3 gene (NOD-like receptor 3, previously known as
1http://clinicaltrials.gov
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FIGURE 1 | Different strategies for IL-1 blockade. Free interleukin (IL)-1b
binds to type 1 IL-1 receptor (IL-1R1) and to the adaptor protein
IL-1RAcP leads to signal transduction (1). Human recombinant IL-1
receptor antagonist (hrIL-1Ra, Anakinra) (2) competes with free IL-1β for the
binding with IL-1R1 but not with the adaptor protein, thus preventing signal
transduction. Rilonacept (3) is a fusion protein comprising the extracellular
domains of the IL-1β receptor (IL-1RI) and adaptor protein (IL-1RAcP)
attached to a human IgG molecule. Its action is to bind to circulating IL-1β.
The same mechanism of action is also valid for Canakinumab (4), a fully
humanized anti-IL-1 monoclonal antibody.
Cold-Induced Autoinflammatory Syndrome 1, CIAS1). Mutations
in this site determine a gain of function of the protein with subse-
quent increased secretion of IL-1β. FCAS represents the milder
phenotype and presents with cold-induced fever, urticaria-like
rash, and constitutional symptoms. MWS represent an interme-
diate form and manifests with fever, urticarial rash, sensorineural
hearing loss, and arthritis usually not related to cold exposure.
CINCA patients, instead, display the worst clinical picture charac-
terized by fever, urticarial rash, epiphyseal overgrowth of the long
bones, and central nervous system involvement (mental retarda-
tion, chronic aseptic meningitis, increased intracranial pressure,
papilledema, cerebral atrophy, sensorineural hearing loss). Almost
1/3 of patients with CAPS may develop amyloidosis that seem to
be more frequent in MWS than in FCAS or CINCA patients.
The active form of cryopyrin (NLRP3) is involved in the assem-
bly of an intracellular multi-protein complex (called inflamma-
some) that play a pivotal role in the activation of Caspase 1, a
cytoplasmatic enzyme responsible for the activation and secretion
of the biological active 17 kD form of IL-1β (10).
The massive secretion of active IL-1β observed in cryopyrin-
mutated individuals, suggested that anti-IL-1 treatment could
represent an effective therapy (10).
Initial isolated case reports showed the dramatic effects of
Anakinra in the control of rash and other systemic manifestations
in MWS (3), FCAS (4), and CINCA (5, 11, 12) patients.
The long-term efficacy and safety of Anakinra in pediatric
CAPS patients has been described in two distinct cohorts of
patients (13, 14).
These two studies indicate that Anakinra treatment is safe and
effective in the long term and should be initiated early, before
irreversible lesions have developed.
Sibley et al. recently published an open label, long-term follow-
up study on a cohort of 26 CINCA/NOMID patients treated with
Anakinra 1–5 mg/kg/day for at least 36 months (15). Twenty-one
out of 26 patients carried mutations in NLRP3 gene and all of
them had an active disease at baseline.
Aim of the study was to evaluate the efficacy and safety of 36 and
60 months of IL-1-blocking therapy in controlling systemic and
organ-specific inflammation and in preventing the progression of
organ damage.
Sustained improvements in diary scores, parent’s/patient’s and
physician’s global scores of disease activity, parent’s/patient’s pain
scores, and inflammatory markers were observed during all the
period of the study. Despite a general good control of clinical
manifestations (including hearing loss, ocular manifestations, and
headache) and laboratory parameters, a few patients displayed a
persistent even if mild inflammation of CNS. Anti-IL-1 treatment
did not prevent the progression of the bone involvement. Over-
all Anakinra was well tolerated and no major adverse effects were
observed.
Kuemmerle-Deschner et al. reported the long-term safety and
efficacy of Anakinra in pediatric and adult patients affected by
MWS. A rapid and persistent control of constitutional symptoms
and organ manifestations was observed (16).
The efficacy of Rilonacept (160 mg/weekly) on CAPS-related
clinical manifestations have been shown in two sequential placebo-
controlled studies performed in patients with FCAS or MWS (17).
The treatment was generally well tolerated. Site reactions in 1/3 of
patients and mild upper respiratory infections were the most com-
mon adverse events (AEs). In 2008, the FDA in USA has approved
its use in CAPS as an orphan drug in adult and children above the
age of 12.
The first evidence for the efficacy of Canakinumab was obtained
by a 48-week, double-blind, placebo-controlled, randomized with-
drawal study, involving 35 MWS patients receiving a subcutaneous
dose of 150 mg (or 2 mg/kg) every 8 weeks (18).
These positive results were confirmed in a 2-years open label
study in which the response to treatment was analyzed in 166
patients (109 Canakinumab-naive and 57 roll-over patients) with
FCAS (n= 30), MWS (n= 103), or NOMID/CINCA (n= 32)
(19). The study showed that a complete response was achieved
in 85 of 109 Canakinumab-naive patients (78%; 79/85 patients
within 8 days, and 5 patients between days 10 and 21). Of
141 patients with an available relapse assessment, 90% did not
relapse, their CRP/SAA levels normalized (<10 mg/l) by day 8, and
remained in the normal range thereafter. Median treatment dura-
tion was 414 days (29–687 days). Notably, upward adjustments of
dose or frequency were needed in 24.1% patients mostly children
with a severe CAPS phenotype (CINCA/NOMID). Predominant
AEs were infections (65.7%) of mostly mild-to-moderate severity.
Serious AE reported in 18 patients (10.8%) were mainly infec-
tions and were responsive to standard treatment. The majority
of patients (92%) reported as having no injection-site reactions
and only 8% of patients reported mild-to-moderate reactions.
Patients receiving vaccinations (15%) showed normal immune
response. Based on these studies, Canakinumab has been approved
in many countries for all forms of CAPS in patients older than
4 years. The first experience on the use of Canakinumab in
daily clinical practice in 13 pediatric CAPS patients has been
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recently reported (20). Globally, patients with a mild-intermediate
MWS phenotype display a complete control of disease activ-
ity maintaining the initial dosage of 2 mg/kg (or 150 mg) every
8 weeks, independently from their age. Conversely, the major-
ity of CINCA patients required to increase the dosage up to
4 mg/kg (or 300 mg) and progressively increase the frequency of
dosing (20).
FAMILIAL MEDITERRANEAN FEVER
Familial Mediterranean fever (FMF) is the most frequent among
hereditary recurrent inflammatory disorders. It presents with an
autosomal recessive pattern of inheritance and is due to muta-
tions in the MEFV (Mediterranean Fever) gene encoding pyrin
(also called marenostrin) (21, 22).
Colchicine represents the treatment of choice for FMF (23).
Nonetheless, approximately one third of the patients have a partial
remission and about 5–10% are non-responders; another 2–5%
do not tolerate the drug mainly due to gastrointestinal symptoms
(24). Data from a large international registry (Eurofever) showed
that almost 40% of FMF patients display an incomplete response
to colchicine, by means of persistent presence of fever attacks or
persistent elevation of acute-phase reactants (25).
Before the advent of colchicine, reactive AA amyloidosis repre-
sented the most frequent and severe complication of the disease.
It occurred in almost 60–75% of patients over the age of 40 with
a poor prognosis. Amyloidosis usually presents in those patients
with severe attacks starting early in infancy but it may develop
even in those patients without clear inflammatory episodes. The
genetic background, the presence of high penetrance mutations,
environmental factors, and the presence of SAA1 gene haplotype
seem to influence the development of amyloidosis too. Even if the
use of Colchicine dramatically reduced the incidence of amyloi-
dosis, a relevant number of patients still present this long-term
complication (26).
Recent evidences have shown that pyrin is able to interact with
some components of the NLRP3 Inflammasome (e.g., ASC and
Caspase 1), raising the hypothesis of a possible role of this pro-
tein as a negative regulator (27, 28) or as an inducer of IL-1β
secretion (29–31). Omenetti et al. have recently reported that
MEFV -mutated monocytes display an increased IL-1β secretion
(32).This over-secretion is correlated to the number and pene-
trance of MEFV mutations (32), confirming the presence of a
dose effect of MEFV mutations already suggested by studies on
FMF animal models (29) and patients (33).
Indeed, the use of IL-1 targeting drugs in colchicine-resistant
FMF patients was recently proposed as a valid therapeutic strat-
egy (27, 34). Anakinra and Canakinumab, have been reported to
be generally effective in case reports and non-controlled series in
more than 30 patients with colchicine-resistant or intolerant FMF
(35–44).
Blocking IL-1 has been used with good results even in a small
cohort of patients with AA amyloidosis and chronic renal failure
(44). In the majority of cases Colchicine was maintained after the
introduction of Anakinra even if at a lower dose.
Normally SAA is completely degraded in the lysosome. It seems
that, in patients with AA amyloidosis, the process of degradation
may be impaired. High levels of SAA due to inflammatory burden
thus worsen the accumulation of this substance. A good control
of the disease by IL-1 blockers with persistent SAA value in the
range of normality, may avoid the worsening of amyloidosis and
may allowed the progressive degradation of the fibrils previously
accumulated.
Recently, Hashkes et al. reported the results of a randomized,
double-blind, single-participant alternating treatment study for
Rilonacept in 14 colchicine-resistant or intolerant FMF patients
(45). Participants were aged 4 years or older and were required
to have an estimated mean of 1 or more FMF attacks per
month for 3 months before screening and 1 or more attacks per
month during screening despite receiving adequate colchicine
treatment. Colchicine intolerance was defined as the inabil-
ity to tolerate the drug at that dose controlling attacks to
fewer than 1 per month. Patients were treated with Rilona-
cept 2.2 mg/kg (maximum, 160 mg) or equal volume of placebo,
both given once weekly by subcutaneous injection. Rilona-
cept significantly reduced the frequency of FMF attacks ver-
sus placebo and ameliorated the physical Health related quality
of life.
TNF-RECEPTOR ASSOCIATED AUTOINFLAMMATORY SYNDROME
TNF-receptor associated autoinflammatory syndrome (TRAPS)
is a rare dominantly inherited disorder, caused by mutations in
the p55 TNF Receptor (or TNFR1), encoded by the TNF Recep-
tor Super Family 1A (TNFRSF1A) gene (46). Fever episodes are
usually prolonged (1–3 weeks) and are usually accompanied by
serositis, arthritis, a skin rash with underlying fasciitis, and peri-
orbital edema. Reactive amyloidosis develops in almost 14–25%
of TRAPS patients and it seems to correlate with the severity and
lasting of fever episodes.
Mutations of TNFR1 lead to a misfolding of the protein that
is thus accumulated in the ER and cytoplasm. This leads to a
response to the unfolded protein with consequent inappropri-
ate cytokine secretion (47). Mitochondrial reactive oxygen species
promote production of pro-inflammatory cytokines and are ele-
vated in TNFR1-TRAPS (48). Moreover, TRAPS patients display
an exhaustion of the autophagy system due to the intracellular
overload of the unfolded mutated protein that represents a further
“stress signal” for the cells (49). This may lead to the activation of
the NLRP3 Inflammasome, consistent with the over-secretion of
active IL-1β observed in TRAPS patients (49).
The inflammatory attacks are usually responsive to high-dose
corticosteroids but side effects limit their use especially in patients
with frequent relapses or nearly continuous symptoms (chronic
course). The use of immunosuppressive drugs have been reported
to be ineffective (50). Since the molecular defect of p55 TNFR is
also associated with an impaired shedding of the receptor from the
membrane surface, the use of Etanercept (Enbrel), was originally
proposed (46).
In a recent study Bulua et al. (51) reported the experience of
15 TRAPS patients enrolled in a prospective, open label, dose-
escalation study using Etanercept. The treatment significantly
attenuated the total symptom score, as well as reduced the fre-
quency of symptoms and the values of acute-phase reactants
during asymptomatic periods. However, during a 10-year follow-
up period, most of the patients discontinued treatment mainly
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due to the lack of efficacy, with a median duration of treatment of
3.3 years.
Of note, the use of anti-TNF monoclonal antibodies (inflix-
imab and adalimumab) has been shown to worsen the inflamma-
tory manifestations in TRAPS patients (52–54).
On the other hand, some anecdotic observations have suggested
an excellent response to Anakinra in some patients (53, 55).
In 2008, the first small cohort of TRAPS patients treated
with Anakinra was described (56). Patients were treated with
Anakinra 1.5 mg/kg/day. All patients had a dramatic response, with
disappearance of symptoms and normalization of acute-phase
reactants. During the following year the patients were treated
continuously with Anakinra and did not experience any disease-
related clinical manifestations or any increase in acute-phase
reactants (56).
Interestingly, data from the Eurofever registry recently showed
the better performance of IL-1 blockade on anti-TNF treatment
in TRAPS patients. In fact, even if Etanercept was beneficial in
32 of the 37 patients, only 11 (30%) experienced a complete
response. Conversely, Anakinra was able to induce a complete
response (absence of clinical manifestations and normalization
of acute-phase reactants) in 26 of 33 patients (79%) and a partial
response in five others (25). The effect of Anakinra in patients car-
rying low-penetrance mutations (e.g., R92Q) seems less striking
in respect to those observed in patients with mutations affecting
cysteine residues (57). The same good results have been prelim-
inary reported in one TRAPS patients treated with the anti-IL-1
monoclonal antibody (Canakinumab) (58).
Interim data of an open label 4-months study with
Canakinumab and of 5-months of follow-up involving 20 active
TRAPS patients have been recently presented, showing the com-
plete control of clinical manifestations and persistent normaliza-
tion of acute-phase reactants (59).
These data support the pivotal role of IL-1β in the pathogen-
esis of TRAPS, but need to be confirmed in a larger number of
patients.
MEVALONATE-KINASE DEFICIENCY
Mevalonate-kinase deficiency (MKD) is due to mutations in
the mevalonate-kinase (MVK) gene (60, 61). MVK is an essen-
tial enzyme in the isoprenoid biosynthesis pathway which pro-
duces several molecules involved in different cellular processes
(62). The severe reduction of the enzymatic activity leads to a
severe multi-systemic disease, named mevalonic aciduria. The
partial enzymatic defect is associated with a normal mental and
physical development, but is characterized by recurrent fever
attacks.
Almost 25% of MKD patients present more than 12 attacks per
years in their second decade of life (17.8% of patients >20 year
old) with a severe impact on quality of life in some patients (63).
Unlike what happen in the other monogenic periodic fevers, amy-
loidosis do not represent a frequent complication of MKD. The
first case of AA amyloidosis was reported in 2004 (64) and few
other patients in the following years (65). van der Hilst et al.
(63) reported a frequency of 2.9% of amyloidosis in a group of
103 patients coming from The International hyper-IgD syndrome
(HIDS) database.
Fever attacks usually respond to the administration of a single
or a few steroids doses. However, due to the high frequency of fever
episodes, some patients may need almost continuous treatment.
Colchicine, cyclosporine, thalidomide, and statins are not effec-
tive (63). The efficacy of biologic treatments is largely anecdotal
and still controversial. Anti-TNF therapy (Etanercept) has been
found to reduce the frequency and intensity of fever attacks in
some patients (66–68) but not in others (69). In the same line
a positive response was also observed after the use of Anakinra
(70–72). The same variable response was also observed in the
International HIDS registry (63).
Galeotti et al. reported the results of a retrospective study aimed
at evaluating the effects on disease activity of an anti-IL-1 treat-
ment in a group of 11 genetically confirmed MKD patients (73).
In this study daily Anakinra (nine patients) or Canakinumab
injections every 4–8 weeks (six patients, in four cases following
Anakinra treatment) were associated with complete remission in
four cases and partial remission in seven.
The rationale for the use of IL-1 blockers is found in studies
from a Dutch group (74) in which the Authors show that a short-
age of isoprenoid end products due to the defective function of
mevalonate kinase contributes to an increased secretion of IL-1β
by MK-deficient peripheral blood mononuclear cells.
In a recent paper Ter Haar et al. analyzed MKD response to
treatment in 67 patients coming from The Eurofever International
Registry2 (25). Anakinra was effective in 24 (89%) of 27 patients
treated, inducing a complete remission in six (22%) of them. Etan-
ercept was effective in 11 (65%) of 17 treated patients, with only
one complete response.
An Open label, Multicenter, Pilot Study of 6-month
Canakinumab Treatment With up to 6-month Follow-up in
Patients With active HIDS is now ongoing to evaluate the efficacy,
the safety, and the pharmacokinetics (PK)/pharmacodynamics
(PD) of Canakinumab treatment in patients with HIDS (see text
footnote 1).
BLAU’S SYNDROME OR NOD2 GENE-ASSOCIATED PEDIATRIC
GRANULOMATOUS ARTHRITIS
Blau’s syndrome is the genetic form of what was previously known
as early-onset sarcoidosis and is due to mutations of the NACHT
domain of the gene CARD15 (or NOD2). It is characterized clini-
cally by the triad of arthritis, skin rash, and uveitis, and histolog-
ically by the presence of non-caseating epithelioid granulomas in
the affected sites that represent the hallmark of the disease. Other,
less frequent clinical symptoms, such as camptodactyly, intermit-
tent fever, cranial neuropathies, and malignant hypertension, have
also been reported (75). The clinical course is variable, but in many
cases the prognosis is poor, with severe disabilities and sequelae in
a high percentage of patients. Eye involvement is frequently pro-
gressive and can lead to panuveitis and severe complications up to
blindness.
An international registry was established in 2005 to collect both
patients affected by Blau syndrome and its sporadic counterpart
of early-onset sarcoidosis that share with the former an identi-
cal phenotype. Rose et al. (76) reported the results of the registry
2http://www.printo.it/eurofever/
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1 year after its creation. In the paper the authors aimed to define
the spectrum of the clinical phenotype and establish the mutation
frequency and variants in patients with “pediatric granulomatous
arthritis.” Up to date this work represent the largest collection of
patients (33 pts) with both sporadic or familiar pedigrees.
Anti-TNF monoclonal antibodies have been shown to be effec-
tive in some anecdotal reports (77, 78). Martin et al. did not
observe evidence for increased IL-1β production in cells obtained
from five subjects with Blau syndrome compared with healthy
control (79). In their study the Authors treat two cases with recom-
binant human IL-1 receptor antagonist without an evident clinical
response. On the other hand few case reports have shown the
effectiveness of IL-1 blockade (75, 80).
PYOGENIC STERILE ARTHRITIS, PYODERMA GANGRENOSUM, AND
ACNE SYNDROME
Pyoderma gangrenosum and acne (PAPA) syndrome is a rare auto-
somal dominant inherited autoinflammatory syndrome charac-
terized by pyogenic sterile arthritis (usually occurring after minor
trauma or even spontaneously) less frequently accompanied by
PAPA. It is associated with dominant missense mutations in the
proline-serine-threonine phosphatase-interacting protein 1 (PST-
PIP1) gene (81, 82). Around 30 cases have been described in the
literature so far. PAPA syndrome is generally responsive to oral
or intra-articular glucocorticoids (81, 82) but anti-TNF has been
reported to be effective in a few patients too (83, 84).
Interestingly, PSTPIP1 is able to interact with pyrin, the pro-
tein mutated in FMF (85). It has also been proposed that pyrin
and PSPTPIP1 form a tri-molecular complex with ASC that is able
to directly recruit and activate Caspase 1 (31).
Mutated PSTPIP1 has increased interaction with pyrin and the
effect of this interaction is similar to that of mutated pyrin, result-
ing in decreased apoptosis and elevated IL-1 levels (85) thus setting
the basis for the use of IL-1 blockade in PAPA patients.
Up to date anecdotal cases of treatment with Anakinra (both
as maintenance therapy or at occurrence) has been reported
with good results particularly on articular manifestations (86–
88). More uncertain is the effectiveness of Anakinra on cutaneous
manifestations.
Geusau et al. have recently reported the successful treatment of
a patient with a PAPA-like syndrome with Canakinumab (89).
This patient, despite the unusual presence of an homozygous
substitution in exon 11 (c.773G>C p.Gly258Ala) in a disease
with an autosomal recessive pattern of inheritance, had a clini-
cal phenotype clearly consistent with a PAPA syndrome. He was
mainly affected by cutaneous manifestations (PAPA fulminans)
since the age of 14 and, despite the absence of arthritis he had
suffered from early childhood of episodes of arthralgia, painful
joints, and fever not responding to antibiotics. Moreover he had
elevated inflammatory markers and white blood cell count with
relative neutrophilia. Notably, the substitution found in this case
had been previously described in an heterozygous symptomatic
PAPA patient3. Soon after the first injection of Canakinumab the
patient displayed a complete remission of the acne and a complete
3http://fmf.igh.cnrs.fr
normalization of acute-phase reactant. Canakinumab was admin-
istered every 9 weeks and no flares were observed in a 9-months
period apart from slight flares of acne at the end of 8 weeks, occa-
sionally accompanied by a moderate increase in C-reactive protein
and serum amyloid A levels (89).
In line with this experience a Phase II Multi Center Open
Label Pilot Study to assess a potential effect of Canakinumab on
Pyoderma Gangrenosum is ongoing (see text footnote 1).
DEFICIENCY OF THE INTERLEUKIN-1-RECEPTOR ANTAGONIST
Deficiency of the interleukin-1-receptor antagonist (DIRA) is a
recently identified autoinflammatory disorder characterized by a
severe systemic inflammation beginning at birth with persistent
inflammation and papular pustulosis. A severe inflammatory bone
involvement (multifocal osteomyelitis,periostitis) is also observed.
The patients display deleterious truncating or missense mutations
in the interleukin-1-receptor antagonist (IL1RN ) gene (90). Dele-
tions at chromosome 2q13, which encompasses several IL-1 family
members, including IL1RN have been reported too (91). As a
result of these mutations, no interleukin-1-receptor antagonist
protein is secreted, with subsequent unopposed action of IL-1.
The patients show a dramatic response to the substitutive treat-
ment with recombinant IL-1 receptor antagonist (Anakinra) (90).
Up to date only 16 cases have been described in literature.
MAJEED’S SYNDROME
The Majeed’s syndrome is an autosomal recessive, autoinflamma-
tory disorder characterized by the triad of chronic recurrent multi-
focal osteomyelitis (CRMO), congenital dyserythropoietic anemia,
and inflammatory dermatosis. The disease was firstly described
in three related Arab children by Majeed and co-workers (92)
and subsequently associated to mutation of the LPIN2 gene (93).
A recent report describe the over production of IL-1 by mono-
cytes of two brothers carrying LPIN2 mutations and the good
response to anti-IL-1 treatment (94), thus showing the possible
pivotal involvement of this cytokine also in this condition.
MULTI-FACTORIAL DISORDERS
The identification of genetically determined inflammatory dis-
eases characterized by a predominant involvement of innate
immunity in respect to the adaptive branch of the immune
response (lack of pathogenic auto-antibodies and antigen-specific
T cells) represented a major breakthrough in the field of inflam-
matory diseases in the last decade. It became clear that several
multi-factorial inflammatory conditions were much more simi-
lar to the recently identified inherited autoinflammatory diseases
rather than to the classical autoimmune rheumatic diseases (RA,
SLE, etc.). Indeed, many multi-factorial disorders present with the
same clinical manifestations observed in inherited autoinflam-
matory diseases (Table 1) and also share the same pathways of
activation of innate immunity.
In fact, it was observed that NLRP3 Inflammasome can be acti-
vated not only by rare, gain of function mutations in the NLRP3
gene but also by a large variety of endogenous or exogenous stim-
uli leading to an over-activation of cells of innate immunity in
different circumstances (95–97). These findings represented the
rationale for the successful use of the anti-IL-1 blockers in many
multi-factorial inflammatory diseases.
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A clear example is given by systemic onset juvenile idiopathic
arthritis (SoJIA) and adult onset Still’s disease (AOSD) that share
with the severe form of CAPS (CINCA) the multi-systemic inflam-
matory involvement (Table 1). SoJIA and AOSD patients classi-
cally present with high spiking fever, arthritis (either with oligoar-
ticular or severe symmetric polyarticular course), and evanescent
rash. Lymphadenopathy, hepatosplenomegaly, serositis, arthral-
gias, and myalgias are frequently present too. Few patients with
SoJIA or AOSD respond to NSAID monotherapy. A single steroid
course can control disease manifestations in patients with mono-
cyclic presentation. However the majority of the patients present
a progression of the disease and develop a steroid dependency.
In these patients Methotrexate or TNF-α neutralizing agents have
been employed with limited success (98, 99). IL-6 has been proven
to play a pivotal role in the pathogenesis of the disease (100)
and IL-6 blockade represent a very effective treatment in steroid-
dependent patients, as recently confirmed by a large international
multicentre trial (101). On the other hand, seminal studies by
Pascual et al. were able to demonstrate the presence of a clear
IL-1 signature in SoJIA patients (102, 103) that, at least in a vari-
able percentage, display an optimal response to IL-1 blockade (98,
103–105). The same observations were also anecdotally reported
in AOSD patients (106, 107). A recent large international trial has
shown that the use of Canakinumab is able to control the articular
and systemic manifestations and allow the tapering and withdrawn
of steroids in a large proportion of patients (108).
Recurrent bouts of seemly unprovoked inflammation are the
most classical manifestation observed in inherited periodic fevers
(Table 1).
PFAPA syndrome is the prototype of a multi-factorial peri-
odic fever syndrome. Patients display recurrent, often clock-wised,
spontaneous episodes of fever in the absence of proof of infec-
tions, associated with an increase of the principal acute-phase
reactant lasting 4–6 days. Usually the disease onset is before the
age of five and aphthous stomatitis, pharyngitis, and laterocervi-
cal lymphadenopathy represent the most characteristic symptoms.
Children present normal growth and complete well-being among
the episodes. The disease is usually self-remitting with the age.
The use of steroid on demand and the tonsillectomy in persistent
cases represent the two main therapeutic strategies. The response
to Anakinra on demand represents the in vivo demonstration of
the in vitro studies indicating the involvement of this cytokine in
the pathogenesis of the disease (109, 110).
Idiopathic recurrent pericarditis also has many features that are
consistent with an autoinflammatory disease. The first observa-
tion of the role of IL-1 blockade in this condition came from
the report on the effect of Anakinra in three steroid-dependent
and colchicine-resistant children (111). Pericarditis recurred when
Anakinra treatment was discontinued and no further episodes
occurred after it was resumed. After this report several others
confirmed the good response to IL-1 blockade (112–114).
Urticarial rash associated with signs of systemic inflammation
represents the classical hallmark of the milder form of CAPS.
Schnitzler’s syndrome share many clinical similarities with these
conditions (Table 1). It is a chronic disabling inflammatory dis-
order, characterized by chronic urticarial rash, paraproteinemia,
and systemic inflammation. Disease onset is usually observed after
the age of 40 and patients can also present fever, bone pain, and
arthralgias or arthritis. A higher risk of developing a lymphopro-
liferative disorder and AA amyloidosis in the long term has also
been reported (115, 116). Anakinra was found to be effective in
over 45 cases to date (117, 118) implying a pivotal pathophysi-
ological role of IL-1. Canakinumab has been tried with optimal
response too. A 9-month open label, single-arm trial demonstrate
the long-term efficacy of Canakinumab in a cohort of 8 Dutch
patients (119).
A prevalent neutrophilic inflammation of joints, bone, and skin
is a common finding in a number of inherited autoinflammatory
diseases (such as PAPA, DIRA, DITRA, etc.), but also in many
multi-factorial disorders (Table 1).
A severe and painful arthritis characterized by a diffuse neu-
trophilic joint effusion is the main clinical feature of gout and
pseudogout, two common conditions occurring in adulthood. The
diseases are caused respectively by the deposition of monosodium
urate (MSU) and calcium pyrophosphate dihydrate (CPPD) crys-
tals in the joints and periarticular tissues. The finding that both
MSU and CPPD crystal are able to activate the NLRP3 inflamma-
some (96) strongly supported the hypothesis that the inflamma-
tory manifestations of these metabolic conditions recognize the
same pathogenic mechanisms observed in inherited autoinflam-
matory diseases, by means of a persistent over-activation of the
NLRP3 inflammasome.
IL-1 blockade has been shown to be effective in colchicine-
resistant gout and pseudogout (120, 121).
Ghosh et al. described the results of Anakinra treatment in 26
patients affected from gout (122). In 67% of them, pain improved
significantly within 24 h and a complete resolution of signs and
symptoms of gout occurred by day 5 in 72.5% of patients. Anakinra
was well tolerated and no adverse outcomes were attributed to the
drug. Only one patient appeared to be refractory to this form of
IL-1 inhibition (122).
In two recent 12-week randomized, multicentre, double-blind,
parallel-group core studies, Canakinumab provided significant
pain and inflammation relief and reduced the risk of new flares in
patients with acute gouty arthritis. AEs reported more frequently
with Canakinumab included infections, low neutrophil count, and
low platelet count (123).
Chronic recurrent multifocal osteomyelitis and Synovitis, Acne,
Pustulosis, Hyperostosis, and Osteitis (SAPHO) syndrome display a
number of clinical similarities with inherited autoinflammatory
diseases characterized by the presence of sterile osteolytic lesions,
such as Majeed’s syndrome and DIRA.
No uniformly effective therapeutic strategies have been estab-
lished for both CRMO and SAPHO (124, 125). Among the various
possible biologic treatments used so far, also IL-1 blockers have
been anecdotally reported to be at least partially effective in both
conditions (124, 126, 127).
Pustular psoriasis and neutrophilic dermatoses are also fre-
quent manifestations observed in inherited autoinflammatory
disease, such as DIRA, DITRA, and CARD14-mediated familial
psoriasis.
Generalized pustular psoriasis is an acute form of psoriasis with
erythematous, painful skin, and widespread sterile pustules asso-
ciated with systemic inflammation (fever, malaise), leukocytosis,
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and elevation of acute-phase reactants. The effect of IL-1 treatment
have been recently described in two patients (128).
Sweet’s syndrome is a neutrophilic dermatosis characterized
by fever, an elevated neutrophil count, and painful erythe-
matous cutaneous lesions. Histopathological analysis reveals a
neutrophilic dermal infiltrate. Systemic corticosteroid therapy
remains the mainstay of the treatment. However recently have
been described few cases with a dramatic response to IL-1 blockage
in patients resistant to standard treatments (129, 130).
Acrodermatitis continua of Hallopeau (ACH) is a rare, chronic
disease characterized by acropustular eruptions predominantly
involving the distal phalanges of the hands and feet with marked
involvement of the nail bed. The sterile pustules may coalesce to
form groups of lesions, which, over time, may spread proximally
to involve the dorsal side of the hands, forearms, and feet. Ony-
chodystrophy and even anonychia of the involved digits, atrophic
skin changes, and osteolysis are often present causing painful and
disabling lesions. In the last years cases responsive to either anti-
TNF (131) and anti-IL-1 (Anakinra) treatments (132) have been
described.
In conclusion, the recent advances in the identification of
the molecular mechanisms leading to the severe inflammatory
response observed in ultra-rare inherited autoinflammatory dis-
eases allow to clarify that similar pathogenic mechanisms play also
a crucial role in sustaining inflammation in a growing number
of multi-factorial disorders. These findings led to a relevant re-
thinking in the classification of the inflammatory diseases (133)
and pointed out the pivotal role of IL-1 as therapeutic target in
these conditions (134). The underlined importance of IL-1 in
the pathogenesis of most of these conditions is reflected by the
high number of clinical trials ongoing with IL-1 blockers (see text
footnote 1).
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